CTSU resubmission: Proposal to increase capacity for methodological improvements in clinical trials

CTSU 重新提交：提高临床试验方法改进能力的提案

• 批准号: MC_EX_G0801669
• 负责人: Rory Collins
• 金额: $ 241.56万
• 依托单位: Medical Research Council
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2008
• 资助国家: 英国
• 起止时间: 2008 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MC_EX_G0801669
• 关键词: CTSU; resubmission; Proposal; increase; capacity

Oxford University?s Clinical Trial Service Unit already provides methodological advice across the different phases of major clinical trials (design, conduct, analysis and interpretation) to a large number of research groups in Oxford, elsewhere in the UK and internationally. It aims to improve the quality of these trials (e.g. more patients recruited more rapidly; better data quality and study conduct) in order that they generate more reliable evidence about the effects of treatments on mortality and major morbidity. MRC hub funding would be used by the CTSU to increase its leadership role in two main areas. Firstly, providing guidance to clinical experts on the design and conduct of trials (chiefly in vascular and neoplastic diseases); and, secondly, developing efficient and secure IT systems to facilitate the conduct of large-scale trials. More reliable evidence from better trials should lead to substantial improvements in public health.

牛津大学的临床试验服务部门已经在主要临床试验（设计，行为，分析和解释）的不同阶段提供了方法学建议，向牛津，英国和国际上的其他地方提供了大量研究小组。它旨在提高这些试验的质量（例如，更多的患者更快地招募；更好的数据质量和研究行为），以便他们为治疗对死亡率和主要发病率的影响提供更可靠的证据。 CTSU将使用MRC中心资金来提高其在两个主要领域的领导作用。首先，向临床专家提供有关试验设计和行为的指导（主要是血管和肿瘤疾病）；其次，开发有效且安全的IT系统以促进大规模试验的进行。来自更好试验的更可靠的证据应导致公共卫生的重大改善。

项目成果

Adiposity and NMR-measured lipid and metabolic biomarkers among 30,000 Mexican adults.

• DOI: 10.1038/s43856-022-00208-2
• 发表时间: 2022-11-14
• 期刊: COMMUNICATIONS MEDICINE
• 作者: Aguilar-Ramirez, Diego;Herrington, William G.;Alegre-Diaz, Jesus;Staplin, Natalie;Ramirez-Reyes, Raul;Gnatiuc, Louisa Friedrichs;Hill, Michael;Romer, Frederik;Trichia, Eirini;Bragg, Fiona;Wade, Rachel;Lewington, Sarah;Collins, Rory;Emberson, Jonathan R.;Kuri-Morales, Pablo;Tapia-Conyer, Roberto
• 通讯作者: Tapia-Conyer, Roberto

Benefits of lowering cholesterol in chronic kidney disease - Authors' reply

降低胆固醇对慢性肾病的好处 - 作者的回复

• DOI: 10.1016/s0140-6736(11)61608-5
• 发表时间: 2011
• 期刊: The Lancet
• 作者: Baigent C

Tobacco smoking and risks of more than 470 diseases in China: a prospective cohort study.

• DOI: 10.1016/s2468-2667(22)00227-4
• 发表时间: 2022-12
• 期刊: The Lancet. Public health
• 作者: Chan KH;Wright N;Xiao D;Guo Y;Chen Y;Du H;Yang L;Millwood IY;Pei P;Wang J;Turnbull I;Gilbert S;Avery D;Kartsonaki C;Yu C;Chen J;Lv J;Clarke R;Collins R;Peto R;Li L;Wang C;Chen Z;China Kadoorie Biobank collaborative group
• 通讯作者: China Kadoorie Biobank collaborative group

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

• DOI: 10.1016/s0140-6736(11)60739-3
• 发表时间: 2011-06-25
• 期刊: LANCET
• 影响因子: 168.9
• 作者: Baigent, Colin;Landray, Martin J.;Reith, Christina;Emberson, Jonathan;Wheeler, David C.;Tomson, Charles;Wanner, Christoph;Krane, Vera;Cass, Alan;Craig, Jonathan;Neal, Bruce;Jiang, Lixin;Hooi, Lai Seong;Levin, Adeera;Agodoa, Lawrence;Gaziano, Mike;Kasiske, Bertram;Walker, Robert;Massy, Ziad A.;Feldt-Rasmussen, Bo;Krairittichai, Udom;Ophascharoensuk, Vuddidhej;Fellstrom, Bengt;Holdaas, Hallvard;Tesar, Vladimir;Wiecek, Andrzej;Grobbee, Diederick;de Zeeuw, Dick;Gronhagen-Riska, Carola;Dasgupta, Tanaji;Lewis, David;Herrington, William;Mafham, Marion;Majoni, William;Wallendszus, Karl;Grimm, Richard;Pedersen, Terje;Tobert, Jonathan;Armitage, Jane;Baxter, Alex;Bray, Christopher;Chen, Yiping;Chen, Zhengming;Hill, Michael;Knott, Carol;Parish, Sarah;Simpson, David;Sleight, Peter;Young, Alan;Collins, Rory
• 通讯作者: Collins, Rory

Randomization is essential for progress in transplant medicine.

随机化对于移植医学的进步至关重要。

• DOI: 10.1097/tp.0b013e31817d4f14
• 发表时间: 2008
• 期刊: Transplantation
• 影响因子: 6.2
• 作者: Baigent C